WallStreetZenWallStreetZen

NASDAQ: ATYR
Atyr Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ATYR

Based on 1 analyst offering 12 month price targets for Atyr Pharma Inc

Min Forecast
$1.00+32.98%
Avg Forecast
$1.00+32.98%
Max Forecast
$1.00+32.98%

Should I buy or sell ATYR stock?

Based on 1 analyst offering ratings for Atyr Pharma Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Hold" rating. Learn More

Be the first to know when Wall Street analysts revise their ATYR stock forecasts and price targets.

ATYR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-07

1 of 1

Forecast return on equity

Is ATYR forecast to generate an efficient return?

Company
90.79%
Industry
62.65%
Market
179.39%
ATYR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ATYR forecast to generate an efficient return on assets?

Company
65.87%
Industry
31.76%
ATYR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ATYR earnings per share forecast

What is ATYR's earnings per share in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
-$0.60
Avg 2 year Forecast
-$0.49
Avg 3 year Forecast
-$0.14

ATYR revenue forecast

What is ATYR's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$10.2M+5,291.58%
Avg 3 year Forecast
$59.4M+31,184.74%
ATYR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ATYR revenue growth forecast

How is ATYR forecast to perform vs Biotechnology companies and vs the US market?

Company
552.81%
Industry
35.12%
Market
13.11%
ATYR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ATYR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ATYR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ATYR$0.75$1.00+32.98%Hold
CING$6.39$36.00+463.38%Strong Buy
PLRX$1.17$2.67+127.95%Buy
NRXP$2.19$38.00+1,635.16%Strong Buy
GRCE$4.67N/AN/A
View Top Biotech Stocks

Atyr Pharma Stock Forecast FAQ

Is Atyr Pharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ATYR) stock is to Hold ATYR stock.

Out of 1 analyst, 0 (0%) are recommending ATYR as a Strong Buy, 0 (0%) are recommending ATYR as a Buy, 1 (100%) are recommending ATYR as a Hold, 0 (0%) are recommending ATYR as a Sell, and 0 (0%) are recommending ATYR as a Strong Sell.

If you're new to stock investing, here's how to buy Atyr Pharma stock.

What is ATYR's earnings growth forecast for 2026-2028?

(NASDAQ: ATYR) Atyr Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.94%.

Atyr Pharma's earnings in 2026 is -$74,118,000.On average, 12 Wall Street analysts forecast ATYR's earnings for 2026 to be -$58,379,692, with the lowest ATYR earnings forecast at -$78,793,954, and the highest ATYR earnings forecast at -$27,797,519. On average, 11 Wall Street analysts forecast ATYR's earnings for 2027 to be -$48,133,340, with the lowest ATYR earnings forecast at -$80,715,758, and the highest ATYR earnings forecast at -$17,502,141.

In 2028, ATYR is forecast to generate -$13,835,026 in earnings, with the lowest earnings forecast at -$71,106,739 and the highest earnings forecast at $81,333,480.

What is ATYR's revenue growth forecast for 2026-2028?

(NASDAQ: ATYR) Atyr Pharma's forecast annual revenue growth rate of 552.81% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.12%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.11%.

Atyr Pharma's revenue in 2026 is $190,000.On average, 12 Wall Street analysts forecast ATYR's revenue for 2026 to be $0, with the lowest ATYR revenue forecast at $0, and the highest ATYR revenue forecast at $0. On average, 11 Wall Street analysts forecast ATYR's revenue for 2027 to be $1,004,436,616, with the lowest ATYR revenue forecast at $0, and the highest ATYR revenue forecast at $7,237,552,163.

In 2028, ATYR is forecast to generate $5,828,262,092 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $20,481,917,675.

What is ATYR's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ATYR) forecast ROA is 65.87%, which is higher than the forecast US Biotechnology industry average of 31.76%.

What is ATYR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ATYR price target, the average ATYR price target is $1.00, with the highest ATYR stock price forecast at $1.00 and the lowest ATYR stock price forecast at $1.00.

The Wall Street analyst predicted that Atyr Pharma's share price could reach $1.00 by Nov 7, 2026. The average Atyr Pharma stock price prediction forecasts a potential upside of 32.98% from the current ATYR share price of $0.75.

What is ATYR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ATYR) Atyr Pharma's current Earnings Per Share (EPS) is -$0.80. On average, analysts forecast that ATYR's EPS will be -$0.60 for 2026, with the lowest EPS forecast at -$0.80, and the highest EPS forecast at -$0.28. On average, analysts forecast that ATYR's EPS will be -$0.49 for 2027, with the lowest EPS forecast at -$0.82, and the highest EPS forecast at -$0.18. In 2028, ATYR's EPS is forecast to hit -$0.14 (min: -$0.73, max: $0.83).

What is ATYR's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ATYR) forecast ROE is 90.79%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.